Pratidin
Society, justice and ethics20 November 2026The Hindu, Page IIGS2GS3

Explained: Why the ban on reusing single-use medical devices divides hospitals and makers

In one line: The DGHS has told all hospitals to stop reusing devices labelled single-use, citing infection risks and overcharging, while hospitals warn of higher costs and want regulated reuse.

Published 20 November 2026. Written by Pratidin from the reports linked at the end; every fact checked by a separate review before publishing. How we work

On 16 October 2026, the Directorate General of Health Services (DGHS), under the Union Health Ministry, wrote to State and Union Territory health secretaries and directors of health services, the Drugs Controller General of India and State drug controllers, prohibiting the reuse of single-use medical devices and disposable surgical items in all public and private health facilities. Facilities must use them strictly as the original manufacturer instructs. The letter said such items were being sterilised and reused in some private and corporate hospitals, particularly in cardiology, nephrology, oncology, cardiothoracic and vascular surgery, and neurosurgery, and that patients or government authorities were sometimes charged the full price. It cited the Drugs and Cosmetics Act, 1940, the Medical Devices Rules, 2017 and the Clinical Establishments Act, 2010, and asked States to inspect and act. The Hindu's explainer of 20 November examines who decides what is safe to reuse.

The DGHS cited cross-infection, device malfunction, loss of performance and procedure-related complications. Devices reported as reused include cardiac, balloon and ablation catheters, guidewires, dialysers and blood tubing, surgical staplers, laparoscopic trocars, orthopaedic drill bits, syringes and needles. Device makers' bodies AiMeD and MTaI welcomed the ban; AiMeD said single-use devices are not necessarily designed or validated for repeated use and that manufacturers should not be liable when devices are reused against their instructions. Hospital chains and associations including AHPI and NATHEALTH sought a rethink, saying costs of complex procedures could rise by 25% to 75%. They cited industry estimates that over 60% of dialysis sessions use multiple-use dialysers, about 40 million treatments a year for about 5 lakh patients, and noted that the Pradhan Mantri National Dialysis Programme allows a dialyser's reuse for the same patient under set conditions.

The explainer argues that manufacturers, who decide which devices are 'single-use', gain from new purchases, and that India lacks consistent reprocessing protocols, tracking and records. It notes that the US Food and Drug Administration regulates reprocessors with the same requirements as original manufacturers, and that Canada, Japan and the European Union also have frameworks. Safe reprocessing needs validated cleaning, integrity checks, performance standards and quality control, not just sterilisation. Suggested steps include a national classification of devices by reusability, reprocessing only in approved facilities with validated methods, and more domestic manufacturing to lower costs. Hospital groups have asked for a three to six month transition and a regulated reuse framework with audits, patient consent, transparent billing and traceability.

Practise this in the app: flashcards, quiz and a timed answer
Prelims

Prelims facts

  • On 16 October 2026 the DGHS prohibited reuse of single-use medical devices and disposable surgical items in all public and private health facilities.
  • The letter cites the Drugs and Cosmetics Act, 1940, the Medical Devices Rules, 2017 and the Clinical Establishments Act, 2010.
  • Hospital groups say costs of complex procedures could rise 25% to 75% and that over 60% of dialysis sessions use multiple-use dialysers.
  • Device makers' bodies AiMeD and MTaI support the ban; AiMeD says manufacturers should not be liable when devices are reused against their instructions.
  • The US FDA treats reprocessors of single-use devices as manufacturers, an example of regulated reprocessing India lacks.

Quick recall

Which body banned reuse of single-use medical devices on 16 October 2026?
The Directorate General of Health Services (DGHS), Union Health Ministry.
Under which Act are the Medical Devices Rules, 2017 made?
The Drugs and Cosmetics Act, 1940.
How many risk classes do the Medical Devices Rules, 2017 use?
Four: A (low), B (low to moderate), C (moderate to high), D (high).
Which body is India's central regulator of medical devices?
The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.
Rise in costs of complex procedures feared by hospital groups?
25% to 75%.
Share of dialysis sessions using multiple-use dialysers (industry estimate)?
Over 60%.
How does the US FDA treat reprocessors of single-use devices?
As manufacturers, with the same requirements.
Which hospital law does the DGHS letter cite?
The Clinical Establishments (Registration and Regulation) Act, 2010.

Prelims practice question

Consider the following laws:
1. Drugs and Cosmetics Act, 1940
2. Clinical Establishments (Registration and Regulation) Act, 2010
3. Consumer Protection Act, 2019
Which of the above were cited by the DGHS in its October 2026 letter banning reuse of single-use medical devices?

  1. 1 only
  2. 1 and 2 only
  3. 2 and 3 only
  4. 1, 2 and 3
Show answer

Answer: (b) 1 and 2 only. The letter cited the Drugs and Cosmetics Act, 1940, the Medical Devices Rules, 2017 made under it, and the Clinical Establishments Act, 2010, along with infection control and biomedical waste provisions. The Consumer Protection Act, 2019 was not among the laws cited.

Use this in UPSC Mains: previous-year questions

Recurring theme: Regulating private healthcare for safety and affordability

  1. 2024 · GS2 · 15 marksCovers one partUse it in the example

    In a crucial domain like the public healthcare system the Indian State should play a vital role to contain the adverse impact of marketisation of the system. Suggest some measures through which the State can enhance the reach of public healthcare at the grassroots level.

    How to use this

    Use the 2026 single-use device ban to show the State regulating market-driven practices in private healthcare, and the cost trade-offs such regulation creates.

    • In October 2026 the DGHS banned reuse of single-use devices after reports that private hospitals reused them and charged patients full price.
    • The ban rests on the Drugs and Cosmetics Act, 1940, the Medical Devices Rules, 2017 and the Clinical Establishments Act, 2010, with States asked to inspect and act.
    • Hospital groups warn costs could rise 25% to 75%; a regulated reprocessing framework and domestic manufacturing can keep care affordable.
Also asked on this theme
  1. 2015 · GS2 · 12.5 marks

    To achieve the desired objectives, it is necessary to ensure that the regulatory institutions remain independent and autonomous. Discuss in the light of experiences in the recent past.

  2. 2015 · GS2 · 12.5 marks

    Public health system has limitation in providing universal health coverage. Do you think that private sector can help in bridging the gap? What other viable alternatives do you suggest?

Mains practice question

The ban on reusing single-use medical devices pits patient safety against the cost of care. Discuss, and suggest a regulatory approach that can serve both. (150 words)

Model answer

On 16 October 2026 the DGHS banned reuse of single-use medical devices in all public and private facilities, citing infection risk and overcharging.

Case for the ban

  • Risks of cross-infection (hepatitis B, C, HIV), malfunction and complications.
  • Patients or government schemes were sometimes charged full price for reused devices.
  • Device makers' body AiMeD says such devices are not necessarily validated for reuse.

Cost concerns

  • Hospital groups (AHPI, NATHEALTH) warn of 25% to 75% higher costs for complex procedures.
  • Over 60% of dialysis sessions use multiple-use dialysers; the PM National Dialysis Programme allows same-patient reuse under conditions.
  • More medical waste and out-of-pocket spending.

A balanced approach

  • National classification of devices by reusability, so labels are not left to manufacturers alone.
  • Reprocessing only in approved facilities, as the US FDA does by treating reprocessors as manufacturers.
  • Caps on reuse, audits, patient consent, transparent billing and traceability.
  • Domestic manufacturing to cut device prices.

Regulated reprocessing can protect patients without pricing them out of care.

The basics

Why this matters

Catheters, dialysers and surgical staplers are often labelled 'single use', yet some Indian hospitals have sterilised and reused them. On 16 October 2026, the Directorate General of Health Services (DGHS) told all public and private facilities to stop.

Who regulates medical devices

Medical devices are regulated under the Drugs and Cosmetics Act, 1940 through the Medical Devices Rules, 2017, administered by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs Controller General of India. The Rules sort devices into four risk classes and require manufacturers to label single-use devices. See Medical Devices Rules, 2017.

What the DGHS letter says

The letter went to State and Union Territory health secretaries and directors of health services, the Drugs Controller General of India and State drug controllers. It said single-use devices were being sterilised and reused in some private and corporate hospitals, especially in cardiology, nephrology, oncology, cardiothoracic and vascular surgery, and neurosurgery, and that patients or government schemes were sometimes charged the full price. Facilities must follow the original manufacturer's instructions. The letter cites the Drugs and Cosmetics Act, the 2017 Rules and the Clinical Establishments Act, 2010.

Two sides of the ban
Hospital groups (AHPI, NATHEALTH, major chains)
  • Costs of complex procedures could rise 25% to 75%
  • Dialysis services could be disrupted
  • Want regulated reuse and a 3 to 6 month transition
vs
Device makers (AiMeD, MTaI)
  • Single-use devices are not validated for repeated use
  • Manufacturers should not be liable for reuse against instructions

Why reuse is risky, and why it happens

Reprocessing means cleaning, disinfecting, testing and sterilising a used device. Done badly, it can leave biological material behind, cause cross-infection such as hepatitis B, hepatitis C or HIV, or let a device fail mid-procedure. These are part of the wider problem of Hospital-acquired infections. Reuse persists partly because devices are costly; a government affidavit in the Supreme Court said mark-ups on hospital consumables could range from 100% to 1,000% or more.

What safe reprocessing needs, beyond sterilisation
  1. 1Validated cleaningRemove all biological material using a tested method
  2. 2Integrity checkConfirm the device is not damaged or weakened
  3. 3Performance testCheck it still works to standard
  4. 4SterilisationKill remaining micro-organisms
  5. 5TraceabilityRecord how many times and on whom it was used

Who decides what is safe?

Manufacturers decide whether to label a device single-use, and they gain when hospitals buy new ones. Several countries therefore allow regulated reprocessing: the US Food and Drug Administration treats reprocessors as manufacturers, with the same duties. The explainer notes that India has historically lacked consistent reprocessing protocols, tracking and record-keeping. That gap is the subject of Regulated reprocessing of devices.

16 October 2026
Date of the DGHS letter banning reuse of single-use devices
It covers all public and private health facilities across India.

Go deeper

Why it matters for UPSC

It is a governance and health question (GS2) with a technology and regulation angle (GS3): how to protect patients without making care unaffordable, and how far a regulator should rely on manufacturers' labels.

The core idea

Devices are regulated under the Medical Devices Rules, 2017, and hospitals under laws such as the Clinical Establishments Act, 2010. Reuse without proper processes can spread Hospital-acquired infections. But blanket bans can raise costs, especially in dialysis. Many countries handle this through Regulated reprocessing of devices, where approved facilities reprocess specified devices under rules.

Numbers and dates to remember

  • 16 October 2026: DGHS letter to States, Union Territories and drug regulators.
  • 25% to 75%: possible rise in costs of complex procedures, per hospital groups.
  • Over 60% of dialysis sessions use multiple-use dialysers; about 40 million treatments a year for about 5 lakh patients (industry estimate).
  • 100% to 1,000% or more: mark-ups on hospital consumables, per a government affidavit in the Supreme Court.
  • Laws cited: Drugs and Cosmetics Act, 1940; Medical Devices Rules, 2017; Clinical Establishments Act, 2010.

Where to go next

Go deeper: safety, cost and the power of the label

For the ban. The DGHS cited cross-infection, device malfunction, loss of performance and procedure-related complications. The device industry body AiMeD welcomed it, saying devices meant for one use are not necessarily designed or validated for cleaning and repeated use. Strong rules on Hospital-acquired infections support this view.

Against a blanket ban. Hospital chains and associations including AHPI and NATHEALTH said costs of complex procedures could rise by 25% to 75%. They pointed to dialysis, where industry estimates say over 60% of sessions use multiple-use dialysers, and noted that the Pradhan Mantri National Dialysis Programme permits reuse of a dialyser for the same patient under set conditions. Doctors have warned of more medical waste and higher out-of-pocket spending.

The middle path. The Hindu's explainer argues that manufacturers, who profit from new sales, should not alone decide what is single-use. It points to regulated frameworks in the United States, Canada, Japan and the European Union and suggests a national classification of devices by reusability, reprocessing only in approved facilities with validated methods, and more domestic manufacturing to cut prices. Hospital groups have asked for similar safeguards: validated sterilisation, caps on reuse cycles, audits, patient consent, transparent billing and traceability. See Regulated reprocessing of devices and Medical Devices Rules, 2017.

Medical Devices Rules, 2017

How devices are classified and controlled.

In one line: The Medical Devices Rules, 2017, made under the Drugs and Cosmetics Act, 1940, govern the manufacture, import, sale and distribution of medical devices in India.

Risk-based control

The Rules place devices in four classes by risk: Class A (low), Class B (low to moderate), Class C (moderate to high) and Class D (high). The higher the class, the stricter the licensing. The Central Drugs Standard Control Organisation (CDSCO) licenses higher-risk devices; State authorities handle lower-risk ones.

Labelling and reuse

The Rules require manufacturers to label single-use devices. That is a labelling rule, not a rule on reprocessing. The DGHS letter of October 2026 relies on these Rules, among other laws, to tell hospitals to follow manufacturers' instructions.

Where to go next

Clinical Establishments Act, 2010

The law that regulates hospitals themselves.

In one line: The Clinical Establishments (Registration and Regulation) Act, 2010 provides for registering hospitals and clinics and setting minimum standards for them.

What it does

Health is a State subject, so the Act applies in States that adopt it and in Union Territories. It requires clinical establishments to register and meet minimum standards of facilities and services, and, under the rules framed under it, to display the rates they charge.

Why it is in the news

The DGHS letter on single-use devices cites this Act along with drug and device laws. Because device law mostly binds manufacturers, rules on what hospitals do with devices depend on establishment-level laws like this one and on State inspection, which the letter asks States to step up.

Where to go next

Hospital-acquired infections

Why reuse can harm patients.

In one line: Hospital-acquired infections are infections that patients pick up in the course of treatment, and poorly cleaned devices are one route.

How devices spread infection

Devices that enter blood vessels or body cavities, such as catheters and guidewires, can carry blood-borne infections such as hepatitis B, hepatitis C and HIV if not properly cleaned and sterilised. Narrow channels in some devices are hard to clean, so biological material may remain even after sterilisation.

The Indian record

Reported cases show the risk: in 2017 Maharashtra's drug regulator reportedly found eight private hospitals had reused 1,306 catheters on more than 1,000 patients, and in 2018 at least 33 people in Bangarmau, Uttar Pradesh, reportedly tested HIV-positive after an unqualified practitioner used an infected syringe.

Where to go next

Regulated reprocessing of devices

The middle path other countries use.

In one line: Regulated reprocessing allows specified single-use devices to be cleaned, tested and reused under strict rules, rather than banning or ignoring reuse.

How it works elsewhere

In the United States, the Food and Drug Administration allows reprocessing of some single-use devices but treats hospitals and third-party reprocessors as manufacturers, with the same duties. Canada, Japan and the European Union also have frameworks.

What it would need in India

Proposals include a national list of devices by reusability, reprocessing only in approved facilities with validated methods, caps on the number of reuses, audits, patient consent, transparent billing and records that trace each device. Hospital groups have asked for such a framework and a three to six month transition; device makers want clear liability rules.

Where to go next

Syllabus

Related stories

Sources used for this summary